IL1RL2 (Recibokibart Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA888016MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
HB0034 research-grade biosimilar; HB 0034 research-grade biosimilar; Recombinant humanized anti-interleukin 36R monoclonal antibody(Huaota Biopharma) research-grade biosimilar ;IL1RL2 antibody; IL1RRP2 antibody; Interleukin-1 receptor-like 2 antibody; EC 3.2.2.6 antibody; IL-36 receptor antibody; IL-36R antibody; Interleukin-1 receptor-related protein 2 antibody; IL-1Rrp2 antibody; IL1R-rp2 antibody
Species Reactivity
Human
Immunogen
Recombinant Human IL1RL2 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to Recibokibart, targeting IL1RL2 (Interleukin 1 Receptor Like 2), also known as IL-36R. IL1RL2 functions as a receptor for IL-36 cytokines, playing a critical role in innate immune responses and inflammatory signaling pathways. Upon ligand binding, IL1RL2 activates downstream NF-κB and MAPK signaling cascades, promoting the production of pro-inflammatory mediators. This receptor is implicated in various inflammatory and autoimmune conditions, including psoriasis, inflammatory bowel disease, and other skin disorders characterized by excessive keratinocyte activation and neutrophil recruitment.

Recibokibart represents a therapeutic antibody designed to block IL-36 receptor signaling, offering potential intervention in IL-36-mediated inflammatory diseases. This biosimilar antibody provides researchers with a valuable tool for investigating IL1RL2 biology, studying IL-36 signaling mechanisms, and exploring therapeutic strategies for inflammatory conditions. It supports studies examining cytokine-receptor interactions, immune cell activation, and disease pathogenesis in relevant experimental models.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for interleukin-36 (IL36A, IL36B and IL36G). After binding to interleukin-36 associates with the coreceptor IL1RAP to form the interleukin-36 receptor complex which mediates interleukin-36-dependent activation of NF-kappa-B, MAPK and other pathways. The IL-36 signaling system is thought to be present in epithelial barriers and to take part in local inflammatory response; it is similar to the IL-1 system. Seems to be involved in skin inflammatory response by induction of the IL-23/IL-17/IL-22 pathway.
Gene References into Functions
  1. Endothelial cells, including dermal microvascular cells, express a functionally active IL-36 receptor. PMID: 27673278
  2. All human blood lymphocytes express IL-36R. PMID: 27269181
  3. The data identify a novel role for IL-36 signaling in colonic inflammation and indicate that the IL-36R pathway may represent a novel target for therapeutic intervention. PMID: 26813344
  4. single nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that is present in approximately 2% of the human population, down-regulated IL-36R signaling by a decrease of interaction with IL-1RAcP. PMID: 27307043
  5. The IL36 receptor (IL1RL2) is an important mediator molecule in the inflammatory response. PMID: 27853811
  6. The ubiquitin-binding Tollip protein contributed to IL-36R signaling and increased the accumulation of both subunits of the IL-36R. PMID: 26269592
  7. IL36A-IL36R axis is modulated in patients with primary Sjogren's syndrome. PMID: 25902739
  8. Expression of IL-1Rrp2 by sone dendritic cell subsets may have an important function in the human immune response in vivo via its role in differentiation of inflammatory Th1 lymphocytes. PMID: 22144259
  9. These data provide evidence that IL-38 binds to the IL-36R, as does IL-36Ra.[IL-38, IL-36R] PMID: 22315422
  10. IL-1alpha and IL-1beta gene polymorphisms do not act as a strong susceptibility factor for MTLE-HS in individuals of Turkish ancestry PMID: 16546408

Show More

Hide All

Subcellular Location
Membrane; Single-pass type I membrane protein.
Protein Families
Interleukin-1 receptor family
Tissue Specificity
Expressed in synovial fibroblasts and articular chondrocytes. Expressed in keratinocytes and monocyte-derived dendritic cells. Expressed in monocytes and myeloid dendritic cells; at protein level.
Database Links

HGNC: 5999

OMIM: 604512

KEGG: hsa:8808

STRING: 9606.ENSP00000264257

UniGene: Hs.659863

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*